Moderna, Inc.

NASDAQ Global Select
Back to all articles
Slightly Bullish +25

11 Best Performing S&P 500 Stocks in the Last 10 Years (2026)

📈 Moderna (NASDAQ:MRNA) is listed among the top 11 best-performing S&P 500 stocks over the last decade with a 925.2% share price gain as of January 18.

💉 The company announced late-stage trial results for its RSV vaccine candidate mRNA-1345, showing 83.7% efficacy against lower respiratory tract disease in older adults.

📉 Deutsche Bank analyst Emmanuel Papadakis raised the price target to $225 but expects Moderna to incur a loss this year due to planned research and development expenses.

🏦 Coatue Management is the largest hedge fund stakeholder with 5.70 million shares valued at $674.7 million as of Q3 2022.

⚠️ Baron Funds highlights underperformance in biotechnology due to uncertainty around booster markets and a shift from government-funded pandemic vaccines to commercial markets.

📊 Moderna is included in a broader list of top performers alongside NVIDIA, Tesla, Microsoft, T-Mobile, UnitedHealth, Lam Research, and ServiceNow.

Bullish Signals
  • Moderna's RSV vaccine candidate mRNA-1345 met core efficacy goals with an 83.7% efficacy rate against lower respiratory tract disease in older adults.
  • Deutsche Bank analyst Emmanuel Papadakis raised the price target from $185 to $225 and maintained a 'Buy' rating despite trimming revenue estimates.
  • Moderna is recognized as a leader in the emerging field of mRNA-based vaccines and therapeutics for infectious, immuno-oncology, rare, cardiovascular, and auto-immune diseases.
Risk Factors
  • Deutsche Bank analyst expects Moderna to incur a loss this year due to planned research and development expenses.
  • Baron Funds notes that Moderna has underperformed the biotechnology sub-industry due to uncertainty regarding the commercialization of mRNA boosters as the market shifts away from pandemic status.
  • Stifel analyst Brian Chin cited declining fundamentals in the memory market and expects investments to contract sharply next year, though this specific comment targets Lam Research rather than Moderna directly.
Full Analysis
The article identifies Moderna (NASDAQ:MRNA) as one of the top-performing S&P 500 stocks over the last decade, citing a 925.2% share price gain as of January 18. The company recently announced positive late-stage trial results for its RSV vaccine candidate, mRNA-1345, which demonstrated an 83.7% efficacy rate against lower respiratory tract disease in older adults. Despite this recent success, Deutsche Bank analyst Emmanuel Papadakis raised Moderna's price target to $225 but maintained a loss estimate for the current fiscal year due to high R&D expenses. Hedge fund sentiment remains mixed, with 44 funds holding positions at the end of Q3 2022, led by Coatue Management which holds a significant stake worth approximately $674.7 million. Baron Funds notes that Moderna has underperformed relative to other biotechnology sub-industries due to uncertainty regarding the commercialization of mRNA boosters as the market shifts from pandemic-driven government funding to a more commercial landscape.